Is Alpelisib safe to be used in the treatment of breast cancer?

Hello,

Welcome to icliniq.com.

I read your query and can understand your concern.

Piqray (Alpelisib) is a targeted therapy medicine used to treat advanced or metastatic hormone receptor-positive (HR+), HER2-negative breast cancer with a PIK3CA mutation. This mutation, which is seen in around 40 % of HR (hormone) positive metastatic breast cancer patients, is capable of activating the PI3K-alpha isoform, increasing cancer cell proliferation and survival. Piqray efficiently targets these mutant cells by reducing PI3K enzyme activity, affecting the PI3K/AKT/mTOR signaling pathway, essential in cancer cell growth.

Piqray differs from other advanced breast cancer therapies in three significant ways:

1. Unlike standard chemotherapy, Piqray's targeted method precisely targets cancer cells with the PIK3CA mutation, reducing the impact on healthy cells.

2. Piqray's interference with the PI3K/AKT/mTOR pathway distinguishes it from other treatment methods, providing a viable therapeutic alternative for individuals who have established resistance to traditional therapies.

3. Piqray's oral tablet form, as opposed to intravenous or intramuscular administration of other drugs, provides patients more ease and flexibility.

However, Piqray's applicability is restricted to certain patient profiles:

1. Piqray's effectiveness is dependent on the existence of the PIK3CA mutation in the patient's malignancy. Piqray must be tested to discover if it is a viable therapy choice.

2. Piqray is usually recommended for people whose cancer has progressed despite hormone treatment. If hormonal treatment continues to be beneficial, Piqray may not be required at that point.

3. Because of the potential adverse effects of Piqray, a comprehensive examination of the patient's overall health is required to determine that they can tolerate the therapy.

In brief, Piqray is an important addition to the therapy spectrum for advanced breast cancer patients with the PIK3CA mutation. Its tailored strategy, distinct mode of action, and simple administration make it a viable choice for patients who have failed previous medications. However, before beginning Piqray medication, it is critical to carefully assess the patient's particular circumstances, including the existence of the PIK3CA mutation, illness progression, and general health.

I hope this helps.

Thank you.Regards.